After Phase III setback – Diamyd sees effect in long-term follow-up
Following its major Phase III setback earlier this year, Diamyd Medical is reporting new positive data. A long-term follow-up of an older study suggests that retogatein may delay progression to insulin-requiring type 1 diabetes in a genetically defined group of children.
The results come from a long-term follow-up of the randomised, placebo-controlled DiAPREV-IT study, which included 50 children with stage 1 or stage 2 type 1 diabetes. Participants were followed for a median of almost 13 years.
In a genetically defined subgroup of children with HLA DR3-DQ2, the estimated median time to stage 3 type 1 diabetes was 9.0 years among those who received two subcutaneous injections of retogatein, compared with 3.4 years in the placebo group.
BREAKING